MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/jcrt.jcrt_2418_24

Медицинская библиотека · Journal of cancer research and therapeutics · 2025

Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR -mutant advanced non-small cell lung cancer.

Chen Nana, Tan Xiaojing, Han Cuiping, Zhao Feng, Yang Lu, Wang Dongfeng, Ye Xin, Wei Zhigang

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

We aimed to verify the efficacy and safety of microwave ablation (MWA) in combination with third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) administration for EGFR-mutant advanced non-small cell lung cancer (NSCLC).

MATERIALS AND

METHODS

Individuals with advanced NSCLC and EGFR mutations who underwent third-generation EGFR-TKI treatment and MWA (EGFR-TKI treatment followed by MWA [Group E + M] and MWA followed by EGFR-TKI treatment [Group M + E]) were retrospectively enrolled. The primary endpoint was duration of response (DoR).

RESULTS

There were 12 patients in Group E + M and 16 in Group M + E. The overall median DoR was 21.9 months (95% confidence interval [CI]: 17.3-26.4). The median DoR was 25.7 months (95% CI: 20.6-30.9) and 20.5 months (95% CI: 5.9-35.1) in Group E + M and Group M + E ( P = 0.996), respectively. When EGFR-TKIs were used as a first-line treatment, the median DoR overall and that of patients in Groups E + M and M + E were 29.3 months (95% CI: 19.2-39.4), 29.3 months (95% CI: 21.0-37.5), and not reached ( P = 0.252), respectively. Major complications related to pneumothorax were observed in five patients, with no difference observed between the groups.

CONCLUSION

Patients with advanced EGFR-mutant NSCLC who underwent third-generation EGFR-TKI treatment plus MWA had a superior DoR and experienced minimal complications.

Для цитирования: Chen Nana, Tan Xiaojing, Han Cuiping, Zhao Feng, Yang Lu, Wang Dongfeng, Ye Xin, Wei Zhigang. Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR -mutant advanced non-small cell lung cancer.. Journal of cancer research and therapeutics. 2025. DOI: 10.4103/jcrt.jcrt_2418_24.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.